This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (7)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Prognosis/ Outcomes  • Pediatric Otolaryngology  • Papillomavirus, Human  • Alert me on articles by topic

Snehal Ruparelia, MPH; Elizabeth R. Unger, MD, PhD; Rosane Nisenbaum, PhD; Craig S. Derkay, MD; William C. Reeves, MD

Arch Otolaryngol Head Neck Surg. 2003;129:1275-1278.

Objective  To determine factors associated with remission of juvenile-onset recurrent respiratory papillomatosis (JORRP).

Design  Longitudinal study.

Setting  Twenty-two tertiary care centers located across the United States.

Study Participants and Methods  The study included 165 patients diagnosed as having JORRP between January 1, 1997, and December 31, 2000. Kaplan-Meier curves and Cox proportional hazards models were used to determine associations between predictors and remission.

Interventions  Surgical excision and drug therapy.

Main Outcome Measures  Remission of JORRP, defined as no surgical procedures for at least 1 year, asassociated with age at diagnosis, drug therapy in the first year after diagnosis, number of surgical procedures in the first year after diagnosis, and number of anatomical sites of disease at diagnosis. Demographic factors (sex and race) and Medicaid status were also evaluated.

Results  Older age at diagnosis was positively associated with remission of JORRP (hazards ratio for every increase of 1 year in age, 1.13; 95% confidence interval, 1.03-1.23).

Conclusions  Younger children were found to have persistent disease and often underwent an increased number of surgical procedures in the first year after diagnosis of JORRP. Sex and race were not important factors in determining remission.

From the Centers for Disease Control and Prevention, Atlanta, Ga (Drs Ruparelia, Unger, Nisenbaum, and Reeves), and the Department of Otolaryngology–Head and Neck Surgery, Eastern Virginia Medical School, Norfolk (Dr Derkay). The authors have no relevant financial interest in this article.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Gefitinib Therapy for Life-Threatening Laryngeal Papillomatosis
Bostrom et al.
Arch Otolaryngol Head Neck Surg 2005;131:64-67.
FULL TEXT